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Abstract 
In addition to surgery, local tumor control in pediatric oncology requires new 
treatments as an alternative to radiotherapy. SN-38 is an anticancer drug with 
proved activity against several pediatric solid tumors including neuroblastoma, 
rhabdomyosarcoma and Ewing sarcoma. Taking advantage of the extremely 
low aqueous solubility of SN-38, we have developed a novel drug delivery 
system (DDS) consisting of matrices made of poly(lactic acid) electrospun 
polymer nanofibers loaded with SN-38 microcrystals for local release in difficult-
to-treat pediatric solid tumors. To model the clinical scenario, we conducted 
extensive preclinical experiments to characterize the biodistribution of the 
released SN-38 using microdialysis sampling in vivo. We observed that the drug 
achieves high concentrations in the virtual space of the surgical bed and 
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penetrates a maximum distance of 2 mm within the tumor bulk. Subsequently, 
we developed a model of subtotal tumor resection in clinically relevant pediatric 
patient-derived xenografts and used such models to provide evidence of the 
activity of the SN-38 DDS to inhibit tumor regrowth. We propose that this novel 
DDS could represent a potential future strategy to avoid harmful radiation 
therapy as a primary tumor control together with surgery. 
Keywords 
Local chemotherapy delivery, SN-38, poly(lactic acid) electrospun nanofibers, 
pediatric solid tumor, pharmacokinetics, microdialysis 
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Introduction 
Treatment of most malignant solid tumors in children relies on a combination of 
local control (surgery and radiation therapy; RT) and systemic chemotherapy 
[1]. Local tumor recurrence after resection surgery and RT remains a challenge. 
Despite local control of high-risk neuroblastoma, local tumor recurrences are 
developed in 10% of newly diagnosed patients and 50% of patients with locally 
persistent re-resected disease [2, 3]. Incidence of local recurrence after first 
complete remission in other pediatric malignancies such as Ewing sarcoma and 
primary localized rhabdomyosarcoma is 25% and 22%, respectively [4, 5]. The 
relevance of an adequate local control is underscored by the worse outcome 
observed in patients that develop local failure after initial complete remission [6]. 
The intensification of RT to improve local control after resection surgery is 
limited by unacceptable toxicity, especially in young children [7], and the 
increased risk of second malignancies [8]. In this context, new technology 
platforms are urgently called for to overcome the drawbacks associated with RT 
after tumor resection in children [9]. 
Polymeric drug delivery systems (DDSs) for the localized delivery of anticancer 
drugs emerged as one of the most promising approaches to treat resectable 
solid tumors [10]. Advantages of localized delivery comprise reduced systemic 
exposure to highly toxic agents and achievement of high local concentration of 
potent anticancer agents that are not suitable for systemic administration due to 
poor aqueous solubility [10, 11]. However, the lack of comprehensive preclinical 
studies aiming to understand the pharmacokinetics of localized DDS in cancer 
still represents a significant hurdle towards a robust bench-to-bedside 
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translation. One of the fundamental questions that remain unanswered is 
whether a substance locally released in the proximity of a solid tumor 
penetrates into the bulk of the malignant tissue or, conversely, the penetration is 
restricted to the tumor margins in direct contact with the DDS. To elucidate this, 
complex imaging techniques [12], radiation [13], or computer simulation [14] are 
usually required. In a previous study, we demonstrated the potential use of 
microdialysis to gain insight into these complex mechanisms in vivo [15]. 
SN-38 (10-hydroxy-campthothecin) in its lactone (active) form is a poorly 
soluble molecule that has shown potent preclinical activity against several 
pediatric solid tumors [16, 17]. Irinotecan, the marketed soluble prodrug of SN-
38, undergoes extensive conversion (>70%) to SN-38 in nude mice [18], though 
it has demonstrated low clinical efficacy, likely due to only partial conversion 
(less than 10%) into the active derivative upon systemic administration in 
patients [19]. In addition, SN-38 is rapidly hydrolyzed to an inactive carboxylate 
form in plasma. The encapsulation of SN-38 into polymeric nanocarriers 
protected it from biodegradation and prolonged the half-life of the active form 
[20]. In this framework, SN-38 emerges as an optimal model anticancer drug to 
investigate the development of a novel DDS for application in the localized 
chemotherapy of pediatric solid tumors. 
Electrospun polymer nanofiber matrices appear as one of the most versatile, 
reproducible and scalable nano-DDS [21]. They allow to adjust their size and 
shape to fill the space left by tumor resection, and provide a large surface area 
and porosity that facilitate the efficient release of the active cargo from the DDS 
to the tumor tissue [21]. Moreover, their monolithic nature eases manipulation, 
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implantation and retention in the action body site, and prevents the 
characteristic migration of nanoparticles and microparticles. 
Following this rationale, the present work reports for the first time on the 
development of a novel nanofiber DDS loaded with SN-38 microcrystals for the 
localized chemotherapy of pediatric solid tumors and the comprehensive 
characterization of the release rate, the in vivo localized biodistribution, the 
systemic pharmacokinetics and the antitumor activity in pediatric solid tumor 
models. A unique feature of the study is the use of microdialysis probes inserted 
in the tissue targeted by the localized release of SN-38 to quantify local drug 
levels at different depths in the tumor bulk or in the virtual space of the resection 
bed [15]. To our knowledge, such sampling technique has not yet been 
employed to monitor localized drug delivery in tumors. 
Materials and methods 
Reagents. SN-38 was obtained from Seqchem (Pangbourne, UK). Poly(lactic 
acid) (PLA) was from Velox, GmbH (Hamburg, Germany). Pluronic® F68 block 
polymer was a gift from BASF (Ludwigshafen, Germany). Irinotecan was 
purchased from Hospira (Lake City, IL, USA). 2-Hydroxypropyl-beta-
cyclodextrin (HPBCD; molecular weight of 1400 g/mol) and dimethyl sulfoxide 
(DMSO) were from Sigma-Aldrich (St. Louis, MO, USA). Methanol was from 
Merck (Darmstad, Germany). RPMI high glucose medium and supplements 
(fetal bovine serum, glutamine, penicillin and streptomycin) were from Life 
Technologies (Grand Island, NY, USA). 
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Preparation of PLA nanofiber matrices loaded with SN-38 microcrystals. 
SN-38 microcrystal suspensions were prepared by pH-dependent crystallization 
the day before the preparation of the nanofiber matrices. The crystallization 
method takes advantage of the pH-dependent reversible equilibrium between 
SN-38 carboxylate (water soluble and predominant at basic or neutral pH) and 
SN-38 lactone (insoluble in water and predominant at acidic pH). To form the 
microcrystals, one volume (100 µL) of SN-38 solubilized in basic pH (4 mg/mL 
in NaOH 0.1 N) was mixed with 9 volumes (900 µL) of pH 5.0 acetate buffer 
containing 2% Pluronic® F68. The mixture resulted in a final pH value of 5.5 
and it was stored at 4ºC for 24 h with hourly agitation during the first 6 h to favor 
the slow precipitation of the SN-38 lactone microcrystals. The size of the 
crystals at 24 h was measured by dynamic light scattering (DLS) with a 
ZetaSizer Nano ZS (Malvern Instruments, Malvern, UK). 
SN-38 microcrystal-loaded nanofiber matrices were prepared by 
electrospinning. PLA (10% in dichloromethane) was loaded in a 2 mL syringe 
and pumped at a constant rate of 0.5 mL/h at a 10 kV voltage. The PLA solution 
was spun for 20 min on a rotating rod wrapped with vegetal paper, to build a 
first layer of SN-38-free nanofibers that would play the role of rate-controlling 
membrane and prevent the direct release of the intact drug microcrystals to the 
physiologic medium. During the following 45 min, the SN-38 microcrystal 
suspension (loaded in a syringe) was pumped (90 µL/min) simultaneously from 
the opposite part of the rotating rod, and sprayed with a pneumatic nozzle. The 
theoretical load of SN-38 in the matrix was 18 µg/cm2. Finally, after loading the 
complete suspension of the drug microcrystals, the PLA solution was spun for 
extra 20 min to generate another free-drug layer that isolates the cargo. Finally, 
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the matrix was dried under vacuum for 24 h, at room temperature. The products 
(SN-38-loaded nanofiber matrices cut into 0.25, 0.5 or 1 cm2 sheets) were 
characterized by scanning electron microscopy (SEM; Phenom G1, Eindhoven, 
The Netherlands), fluorescence microscopy (Leica DM 5000 B, Wetzlar, 
Germany), and differential scanning calorimetry (DSC 2 STARe system 
simultaneous thermal analyzer with STARe Software V13, Mettler-Toledo, 
Schwerzenbach, Switzerland) equipped with intra-cooler Huber TC100 under 
dry N2 atmosphere and In as standard. The amount of SN-38 loaded in the 
matrices was analyzed by extraction of the drug with methanol and injection of 
the extract in a high-performance liquid chromatography (HPLC) system with 
fluorescence detector, as previously described [15]. 
SN-38 release. Several in vitro and in vivo experiments characterized the 
release profile of SN-38 from the matrices upon dissolution of internal SN-38 
microcrystals in physiologic conditions. 
In vitro, SN-38 matrices containing 5 µg SN-38 in 0.25 cm2 (n = 24) were placed 
in glass vials with 5 mL of pre-warmed PBS (pH 7.4) and incubated at 37ºC 
away from light. At time points 0.25, 2, 4, 8, 24, 48, 72 and 96 h, three matrices 
were removed from the vials for drug analysis by HPLC. The removed matrices 
were vigorously vortexed in 5 mL methanol to extract the unreleased SN-38 for 
analysis. The release medium of the remaining matrices was completely 
replaced with fresh pre-warmed PBS at all sampling times. 
We repeated the in vitro release experiment described above though in the 
presence of the solubilizer HPBCD (10% w/v in PBS). The sampling times in 
these experiments were 0.25, 0.5, 0.75, 1, 2, 4, 8 and 24 h. 
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In a third experiment, 0.25 cm2 matrices containing 5 µg SN-38 crystals were 
introduced in 24 well plates containing 400 µL of cell culture medium (RPMI 
supplemented with 10% FBS, 2 mM L-glutamine, penicillin 100 U/mL and 
streptomycin 100 μg/mL) at 37ºC. We used culture medium to simulate the 
conditions of the in vitro cytotoxicity studies. The complete volume was 
removed for HPLC analysis at 8 h and renewed with fresh medium. At 24 h, SN-
38 release was analyzed again. 
Finally, SN-38 release in vivo was evaluated using 0.5 cm2 matrices containing 
9 µg of SN-38 and subcutaneously (s.c.) implanted in 12 mice. Mice were 
sacrificed and matrices were removed at different time points (1, 4, 24 and 48 
h). The amount of SN-38 remaining in the matrices was extracted with methanol 
and analyzed as already described. 
Tumor models. Pediatric solid tumor models (neuroblastoma cell lines LAN-1 
and SK-N-AS, Ewing sarcoma cell line SK-ES-1 and rhabdomyosarcoma cell 
line Rh30) were obtained from the repository maintained at Hospital Sant Joan 
de Déu (HSJD, Barcelona, Spain). Two patient-derived xenografts (PDX), 
HSJD-NB-005 (neuroblastoma) and HSJD-ES-001 (Ewing sarcoma) were 
established and maintained in athymic nude mice (Harlan, Barcelona, Spain) as 
previously described [15, 22]. Primary cultures were established by 
disaggregation of the PDX models with collagenase-DNase enzymes (Sigma-
Aldrich). Additional information of the PDX models is available in Table 1 and 
published elsewhere [23]. The research performed with mice was approved by 
the institutional ethics committee. 
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In vitro activity. The MTS assay (Promega, Fitchburg, WI, USA) was used for 
determination of cell viability after in vitro cytotoxicity experiments. Each 
treatment condition was assayed at least in triplicate. 
To determine the activity of SN-38 against the pediatric solid tumor cell models 
(LAN-1, SK-N-AS, SK-ES-1 and Rh30 cell lines; HSJD-NB-005 and HSJD-ES-
001 primary cultures), we performed assays in 96 well-plates with 3000 cells 
per well and 3-4 days of incubation with the drug (stock solubilized in DMSO), 
as previously described [24]. 
The activity of the SN-38 matrices (0.25 cm2; 5 µg SN-38) was studied in 24-
well plates. For this, 12,000 cells were plated in each well and cultured until 
they formed monolayers of tumor cells covering the growth area of 1.9 cm2 
provided by the well. In a first experiment, SN-38 matrices were added to the 
culture monolayers and removed after 8, 24, 48 and 96 h, renewing the culture 
medium at each time point. After 96 h, cell viability was determined as 
described before. Blank matrices (no SN-38 content) were used as a control. 
In a second experiment, SN-38 matrices were preconditioned in cell culture 
medium without cells (400 µL) at 37 ºC for 24 or 48 h. After the preconditioning 
stage, the matrices were transferred to the wells with cell monolayers in culture. 
Thus, a significant fraction of the drug would have been released before cell 
treatments. After 72 h of incubation, the matrices were removed and the viability 
of the cells was determined. 
In a third assay, blank matrices and SN-38-loaded matrices were co-incubated 
for 24 h in 24-well plates containing 400 µL cell-free culture medium. Thus, SN-
38 from drug-loaded matrices that underwent solubilization in the medium could 
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be absorbed by blank matrices during the co-incubation time. Then, all the 
matrices were washed by fast immersion in cold PBS, and transferred to 24 
well-plates containing tumor cells monolayers in culture. Cell viability was 
determined after 72 h. 
Systemic pharmacokinetics. One cm2 SN-38-loaded matrix containing 18 µg 
SN-38 was implanted s.c. in 6-weeks old athymic nude mice (n = 13). Such 
administration provides a 1 mg/kg SN-38 dose (the average weight of the mice 
was 18 g). At 0.25, 0.5, 1, 3, 6, 12, 24 and 48 h after matrix implantation, mice 
were bled (50 µL) by the retroorbital plexus. 
A second group of mice received an intravenous injection of irinotecan at an 
equimolar dose (44 µg irinotecan trihydrate in 100 µL vehicle) and they were 
bled at 0.25, 1, 4 and 10 h after injection. To calculate the equimolar dose of 
irinotecan and SN-38, we considered published work in which 70% of systemic 
irinotecan is converted to SN-38 in nude mice [18]. 
A maximum of 3 blood samples were obtained from each mouse. SN-38 in 
plasma was analyzed as previously described [15]. We used the trapezoid 
method to calculate the area under the concentration-time curve (AUC) of SN-
38 lactone in plasma. 
Local pharmacokinetics of SN-38 matrices in the surgical bed. To study the 
release of soluble SN-38 in the virtual space of the subcutaneous surgical bed 
upon administration of SN-38 matrices or soluble prodrug irinotecan, we 
performed a series of in vivo microdialysis experiments in 9 nude mice, as 
previously described [15]. First, we inserted a CMA 20 microdialysis probe 
(CMA, Kista, Sweden) s.c. in the flank of the mouse, under isoflurane 
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anesthesia. The probe was infused continuously with perfusate (PBS containing 
10% HPBCD) using an infusion pump at 0.5 µL/min. The microdialysis probe 
was stabilized for 1 h before the administration of the dose. A first group of mice 
(n = 3) was anesthetized with isoflurane, a small incision was made in the skin 1 
cm away from the probe, and a 1 cm2 SN-38 matrix (18 µg SN-38; 1 mg/kg) 
was inserted between the probe and the mouse skin. The wound was sutured 
with clips. A second group (n = 3) was slightly anesthetized with isoflurane to 
receive a local injection of irinotecan s.c. in the probe area, at a dose (44 µg 
irinotecan in 100 µL) that was equimolar to the one used for SN-38. A third 
group (n = 3) received 44 µg irinotecan intravenously. Dialysate samples were 
collected in an autosampler and analyzed by HPLC [15]. Probes were calibrated 
using the mean recovery value (70%) previously determined in vivo at steady 
state SN-38 plasma levels [15]. Blood samples (30 µL) were obtained at 0.25, 1, 
4 and 24 h after dose administration and every 24 h until the end of the 
experiment with SN-38 matrices; and at 0.25, 1, 4 and 10 h after irinotecan 
injections. After HPLC analysis, we calculated the AUC of SN-38 lactone in the 
surgical bed and plasma from each individual microdialysis experiment. 
Diffusion of locally released SN-38 through the solid tumor tissue. To 
investigate the depth of local SN-38 diffusion into the extracellular fluid (ECF) of 
tumor tissue upon localized release in the tumor periphery by SN-38 matrices, 
we implanted (s.c.) the HSJD-NB-005 PDX model in one flank of 16 mice. 
When the tumor reached a diameter of at least 10 mm, we anesthetized the 
mice with isoflurane and inserted a microdialysis probe into the tumor. The 4 
mm length probe was introduced so that it was aligned in parallel to the tumor 
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surface, at a determined distance from the tumor surface (range 0-8 mm, 
depending on each individual experiment). 
After probe equilibration, a small incision was made in the skin 1 cm away from 
the probe, and a 1 cm2 SN-38-loaded matrix (18 µg SN-38; 1 mg/kg) was 
inserted in 14 mice between the probe and the mouse skin. In a subgroup of 2 
mice, the SN-38 matrix was implanted in the contralateral flank. The wound was 
sutured with clips. Dialysate samples were taken overnight. At the endpoint of 
the experiment the probe was perfused with methylene blue to stain the probe 
track, the tumor was sectioned transversally to the probe track and the distance 
between the blue track and the SN-38 matrix was measured with a caliper. After 
HPLC analysis, we calculated the AUC (0-9 h) of SN-38 lactone in tumor ECF 
from each individual microdialysis experiment. 
In vivo antitumor activity. We evaluated the local activity of the SN-38 
matrices in the PDX models HSJD-NB-005 and HSJD-ES-001. In a first set of 
experiments, both tumor models were implanted s.c. in both flanks of n = 8 and 
n = 7 mice, respectively. When the tumors reached 1000-2000 mm3, we 
performed a subtotal resection surgery under ketamine-xylazine anesthesia. At 
that point, tumors were infiltrating the surrounding tissues (muscle and skin). 
Most of the tumor volume was macroscopically removed from both flanks with 
the exception of a well-vascularized and viable tumor fragment of approximately 
2 x 1 mm (length x width). We covered such tumor rest with one SN-38 matrix in 
one flank, and a blank matrix in the opposite. Wounds were closed with clips 
and the animals recovered. The size of tumor recurrences in both flanks was 
measured with a caliper at different time points during the following 3 weeks. 
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Finally, we run a survival experiment in the HSJD-NB-005 PDX model. For the 
survival studies, 31 nude mice bearing s.c. tumors of 0.1-0.5 cm3 in one flank 
were randomized in 4 groups of 7-8 mice for subtotal tumor resection surgery. 
One group received local SN-38 matrix (18 µg SN-38); a second group was 
treated with equimolar local s.c. irinotecan; a third group received equimolar 
systemic irinotecan (via intraperitoneal injection); and a fourth group received a 
blank matrix on the tumor bed. Tumor recurrences were measured 3 times a 
week and mice were sacrificed when the tumor diameter reached 2 cm3. The 
study finalized at day 100 post-resection surgery. Animal survival was defined 
as the time interval between the initial date of treatment and the date in which 2 
cm3 tumor volume was reached. 
Statistics. Statistical analysis was performed with Graphpad Prism 5 software 
(La Jolla, CA). Aggregate data are presented as mean ± SD. Pharmacokinetic 
data was log-transformed before analysis and the one-way ANOVA test with 
Bonferroni’s multiple comparison was used to compare parameters between 
groups. Paired t test was used to compare tumor size in treated animals with 
tumors in both flanks (treated versus control). Median survivals were calculated 
using Kaplan-Meier curves and the log-rank test with Bonferroni-corrected 
threshold was applied for comparison of multiple survival curves. 
Results 
Characterization of SN-38-loaded matrices. The size of the SN-38 
microcrystals before spraying in the nanofiber matrices was 1.7 ± 0.34 µm 
(mean ± SD z-average; poly-dispersion index 0.201). SEM analysis of dry 
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matrices showed the presence of SN-38 microcrystals on the surface of PLA 
nanofibers, covered by a thin layer of surfactant (Figure 1A). The presence of 
SN-38 microcrystals in the internal layer of the matrix (Figure 1B) but not in the 
external layer (Figure 1C) was also detected by fluorescence microscopy. 
DSC analysis provided comparable thermograms of blank matrices and SN-38-
loaded matrices that included characteristic thermal transitions of semi-
crystalline PLA, with the exception of an endothermal peak at 232 ºC in the 
latter that was consistent with the presence of crystalline SN-38 (Figure 1D). 
Drug load was analyzed in 1 cm2 SN-38 matrices containing a theoretical load 
of 18 µg SN-38/cm2. Loading efficiency was 97.7 ± 9.2 % (mean ± SD; n = 9). 
Figure 1. Physical characterization of the SN-38-loaded matrices. A. SEM micrograph 
of the internal layer of the nanofiber matrix. Note the fibers are covered by a layer of 
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surfactant (Pluronic F68). SN-38 microcrystals are labeled with arrows. B. Fluorescent 
image of SN-38 microcrystals in the internal layer of the matrix. Bar = 10 µm. C. 
Absence of fluorescent SN-38 microcrystals in the external layer of the matrix. Bar = 10 
µm. D. DSC thermograms of SN-38-loaded and SN-38 free (blank) matrices. The 
endothermal peak at 232 ºC in the SN-38-loaded matrices corresponds to crystalline 
SN38. 
SN-38 release from matrices. Figure 2A shows the in vitro release profile 
from SN-38-loaded matrices incubated in the absence of HPBCD solubilizer. 
Release was sustained in time and achieved 72.1 ± 10.6% of the payload after 
96 h of incubation. Unreleased SN-38 remained mainly in the lactone form (98.5 
± 0.2%) and not in the carboxylate one (1.5 ± 0.2%). Drug analysis was not 
performed in the release medium because, in the absence of HPBCD, SN-38 
extensively binds to glassware and plasticware, leading to irreproducible results 
[15]. As expected, the addition of HPBCD permitted reproducible drug analysis 
in the release medium in a cumulative release experiment (Figure 2B). Due to 
the presence of HPBCD in the release medium, the released SN-38 was water-
solubilized and the matrices were completely deprived of the cargo within 24 h; 
drug load in the matrices was 0.49 ± 0.77% at the end of the study. In vivo 
release data from individual SN-38 matrices overlapped the in vitro release 
curve (Figure 2A). SN-38 remaining in the matrices of the in vivo assay was 
mainly lactone (93.1 ± 3.2%) over carboxylate SN-38 (6.9 ± 3.2%) at all the time 
points. In culture medium, SN-38 matrices achieved concentrations above 1 µM 
(range 0.88-6.07; n = 6) after 8 h of incubation, and above 0.1 µM at 24 h 
(range 0.14-3.54; n = 6) (Figure 2C). 
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Figure 2. Release from the SN-38 matrices. A. In vitro release profile without 
solubilizer. The remaining amount of SN-38 was analyzed in individual matrices (n = 
24; black dots). In vivo release data (red dots) are superposed in the in vitro curve. 
Each dot represents one individual matrix removed from one mouse (n = 12). B. 
Cumulative in vitro release profile from SN-38 matrices in the presence of HPBCD in 
the release medium (n = 3). Values were corrected to 100% upon analysis of the 
remaining amount of SN-38 in the matrices at the end of the experiment. C. 
Concentrations achieved in cell culture medium (400 µL) upon incubation of SN-38 
matrices containing 5 µg SN-38 during 8 or 24 hours (n = 6). 
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In vitro activity. As shown in Table 2, all the pediatric solid tumor cell models 
employed in the study were sensitive to SN-38, and the concentrations causing 
50% decrease in cell proliferation (IC50) were in the nM range. The proliferation 
of culture monolayers exposed to SN-38 matrices was significantly reduced 
even at short exposures (8 h), as compared to blank matrices that did not 
induce changes in cell proliferation (Figure 3A). SN-38-loaded matrices 
preconditioned in cell culture medium during 24 or 48 h conserved their 
antiproliferative activity when transferred to cell monolayers in culture (Figure 
3B). Blank matrices co-cultured with SN-38 matrices and transferred 
subsequently to cell cultures did not acquire antiproliferative activity (Figure 
3C). 
Figure 3. Antiproliferative activity of the SN-38 matrices. A) Activity of the SN-38 
matrices against pediatric cell culture monolayers upon exposures ranging 8-96 h. 
Blank matrices did not exhibit antiproliferative activity. B) SN-38 matrices 
preconditioned in cell culture medium during 24 or 48 h conserved their activity, as 
compared to the activity of the not preconditioned (intact) formulation. C) Blank 
matrices co-incubated with SN-38 matrices during 24 h did not acquire antiproliferative 
activity, whereas co-cultured SN-38 matrices conserved their activity as compared to 
the activity of the intact SN-38 matrices. All the experiments were performed in 
triplicate. 
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Plasma pharmacokinetics. SN-38 lactone levels in mouse plasma are shown 
in Figure 4. Mice receiving SN-38 matrices achieved median lactone SN-38 
peak plasma level (Cmax) of 1.05 ng/mL (range 0.53-1.27) at 1 h after s.c. 
insertion. SN-38 plasma concentrations were below the limit of quantification 
(0.25 ng/mL) at 12 h. The calculated AUC (0-6 h) was 3.78 ng*h/mL. After 
intravenous injections, SN-38 plasma levels were fitted to a two compartment 
model and the extrapolated Cmax was 122 ng/mL and the calculated AUC (0-7 
h) was 104 ng*h/mL.
Figure 4. Plasma concentration-time data of SN-38 lactone upon administration of 
equimolar dosages of SN-38 matrices (1 mg/kg; s.c.; local matrix) and systemic 
irinotecan (i.v. IRN) in nude mice (n = 13 and n = 4, respectively).  
SN-38 pharmacokinetics in the surgical bed. Lactone SN-38 concentrations 
were quantified in the s.c. space and plasma from mice with microdialysis 
probes placed in the s.c. surgical bed (Figure 5). SN-38-loaded matrices 
induced high drug concentrations in the surgical bed (408 ± 284 ng/mL; mean 
concentration during the first 12 h of three experiments). Such levels were 
sustained and above 10 ng/mL (i.e. 25 nM; above the IC50 in 4 out of 6 cell 
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models shown in Table 2) until the end of the 4-day microdialysis experiments. 
A representative experiment in which the probe was in close proximity to the 
SN-38 matrix is shown in Figure 5A. In comparison, local s.c. injection of 
equimolar irinotecan achieved peak levels in the surgical bed of 41.6 ± 3.4 
ng/mL (mean Cmax from 3 experiments), which dropped to less than 10 ng/mL 
after 7 h (Figure 5B). Maximum SN-38 levels in the surgical bed of mice 
injected i.v. were 3.55 ± 1.16 ng/mL and they were below 0.25 ng/mL, the limit 
of quantification (L.O.Q.), after 6 h (Figure 5C). 
Figure 5. SN-38 pharmacokinetics in the s.c. surgical bed and in plasma upon 
administration of equimolar doses from s.c. SN-38 matrices (1 mg/kg) or irinotecan 
(IRN), either s.c. or i.v. Representative individual experiments are shown in A (SN-38 
matrix, s.c.), B (IRN s.c. local), and C (IRN i.v.). Black dots represent SN-38 levels 
(dialyzable fraction, recovery-corrected) in the virtual space of the s.c. surgical bed. 
Red triangles are plasma data. L.O.Q: Limit of quantification (0.25 ng/mL). D. SN-38 
AUCs in surgical bed and plasma. E. Surgical bed-to-plasma SN-38 AUC ratios. Data 
are mean ± SD from triplicate experiments. *P < 0.01 and **P < 0.001 as compared to 
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IRN i.v. and IRN s.c. local groups (one-way ANOVA test with Bonferroni’s multiple 
comparison). 
SN-38 plasma levels were slightly above the L.O.Q. only until 6 h in mice 
receiving SN-38 matrices, as compared to higher plasma levels in mice 
receiving irinotecan s.c. or i.v. (Figure 5A-C). SN-38 exposure (AUC) in the 
surgical bed surrounding the SN-38-loaded matrices, and surgical bed-to-
plasma AUC ratio, were at least 2 logs higher as compared to the exposures of 
animals receiving s.c. or i.v. irinotecan (Figures 5D and 5E). Concomitantly, 
plasma AUC in animals receiving SN-38-loaded matrices was lower than in 
counterparts receiving irinotecan s.c. or i.v (Figure 5D). 
Diffusion of locally released SN-38 through the solid tumor tissue. Upon 
measuring the distance between the peritumoral SN-38-loaded matrix and the 
intratumoral microdialysis probe track at the experimental endpoint, we grouped 
the experiments in distance ranges of 0-1 mm (n=4), 1-2 mm (n=3), 2-5 mm 
(n=4), and 5-10 mm (n=3). Release from SN-38-loaded matrices resulted in 
significantly higher SN-38 concentrations in tumor ECF when the probe was 
placed up to 2 mm distance from the matrix, as compared to when such 
distance was >2-5 mm (P < 0.05; Figure 6A). Mean SN-38 concentration 
achieved in the 2-5 mm distance range experiments was 2.0 ± 1.1 ng/mL (i.e., 
5.1 ± 2.8 nM) and thus it was below the IC50 of 4 out of 6 cell models studied in 
this work (Table 2). SN-38 in tumor ECF was undetectable at distances greater 
than 5 mm or when it was released in the flank contralateral to the tumor. 
Tumor SN-38 exposures (AUC 0-9 h) were significantly higher in the < 1 mm 
and 1-2 mm distance groups, as compared to the 2-5 mm group (P < 0.01 and 
P < 0.05; Figure 6B). Exposures were below the detection limit when the 
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distance between tumor and probe was greater than 5 mm. Two representative 
microdialysis experiments are shown from mice with s.c. probes located either 
in close contact with the matrix (Figure 6C; < 1 mm) or distant from the matrix 
(Figure 6D; 4 mm). 
Figure 6. Intratumor penetration of SN-38 upon administration of SN-38 matrices. A. 
SN-38 concentrations in tumor ECF sampled by an intratumoral microdialysis probe 
positioned at different depths (< 1 mm, 1-2 mm, 2-5 mm, 5-10 mm) relative to the 
position of the SN-38 matrix covering the tumor periphery. Mean ± SD concentrations 
during the first 9 h of 3-4 experiments are shown. “Contralateral” refers to experiments 
in which the SN-38 matrix was located s.c. in the flank contralateral to the intratumoral 
probe (n = 2 experiments). B. AUC data obtained in each relative position (mean ± SD). 
C, D. Individual microdialysis experiments showing plots of SN-38 levels in tumor ECF. 
Side pictures in C and D are corresponding tumor sections displaying the relative 
position between the probe track (black arrow) and the SN-38 matrix (empty arrow). 
The distance track-matrix was < 1 mm in C and 4.3 mm in D. BLQ: Below limit of 
quantification. *P < 0.05 as compared to the 2-5 mm group (one-way ANOVA test with 
Bonferroni’s multiple comparison). 
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In vivo antitumor activity. SN-38 matrices delayed tumor growth in the 
surgical bed after subtotal resection of PDX models HSJD-NB-005 and HSJD-
ES-001. Contralateral tumors receiving blank matrices were significantly larger 
than the treated ones at the studied time points (P < 0.05; paired t test; Figure 
7). 
Figure 7. In vivo activity of the SN-38 matrices in HSJD-NB-005 (A) and HSJD-ES-001 
(B) PDX models after subtotal bilateral tumor resection. Time from surgery until 
recurrence in the tumor side treated with SN-38 matrices (SN-38) was significantly 
delayed as compared to recurrence in the opposite flank treated with blank matrix 
(Blank). Mean and SD data from 8-11 mice with bilateral tumors are represented. *P < 
0.05 (Paired t test). Sampling times are different between both models because of 
different tumor growth kinetics. 
Survival. Median survival of the animals receiving SN-38-loaded matrices (n = 
8), blank matrices (n = 8), s.c. irinotecan (n = 7) and systemic irinotecan (n = 8) 
after subtotal tumor resection was 76, 37, 46 and 40 days, respectively (Figure 
8). Mice treated with SN-38-loaded matrices after surgery survived significantly 
longer than mice treated with blank matrices (P = 0.0068). In contrast, localized 
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s.c. or systemic irinotecan did not provide a significant benefit in animal survival 
(P = 0.3292 and P = 0.5944, respectively) as compared to blank matrices. 
Treatment with SN-38 matrices performed better than s.c. irinotecan (P = 
0.0080). Difference in survival between the SN-38-loaded matrix group and the 
systemic irinotecan group was not statistically significant (P = 0.120). 
Figure 8. Survival of mice bearing HSJD-NB-005 tumors, upon subtotal resection and 
treatment with local SN-38 matrices (SN-38 matrix) or control treatments (Blank matrix, 
systemic IRN, s.c. IRN). Median survival of each group was determined and the 
Bonferroni-corrected threshold was applied for comparison of multiple survival curves 
(i.e. for 4 groups, there are 6 pairwise comparisons). With the Bonferroni correction, P 
< 0.0083 was considered significant. * P = 0.0080 as compared to control group (Blank 
matrix). 
Discussion 
Local tumor control in pediatric oncology requires new treatments in addition to 
surgery, to delay or replace radiotherapy. However, such innovative treatments 
are currently unavailable in the clinic. Motivated by this unmet need, we have 
developed a clinically translatable nano-DDS for the local release of SN-38, a 
poorly-water soluble camptothecin with proved antitumor activity against several 
pediatric solid tumors. To select the surgical scenarios in which the new system 
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would be suitable, we first conducted preclinical experiments to characterize the 
distribution of the released drug in the surgical bed and in the tumor bulk, using 
microdialysis sampling in vivo. We observed that the released drug achieves 
high concentrations in the virtual space of the surgical bed and it penetrates a 
maximum distance of 2 mm within the bulk of the tumor. Therefore, we propose 
that surgeries achieving macroscopically complete resection or minimal tumor 
residues surrounding vital structures could be optimal candidates for the new 
treatment strategy. Subsequently, we developed a model of subtotal tumor 
resection in clinically relevant pediatric PDX models and we used such model to 
provide evidence of the activity of the SN-38 DDS to inhibit tumor growth after 
surgical resection. 
Irinotecan is potently active as single agent in preclinical models of 
neuroblastoma [17], rhabdomyosarcoma [25] and Ewing sarcoma (own results 
in PDX models, unpublished). In our present study, we confirmed the potency of 
its active metabolite SN-38 against pediatric cancer cell lines and against 
primary cultures derived from PDX models established at our institution (Tables 
1,2 and Figure 3). However, irinotecan in pediatric cancer clinical trials has not 
replicated the reported preclinical activity, either as single agent [26, 27] or 
combined with other drugs [28]. The reasons for this lack of correlation between 
preclinical and clinical efficacies are not totally understood, but they could be 
related to suboptimal SN-38 distribution in human tumors. Greater activity of 
murine carboxylesterases (the enzymes required to metabolize systemic 
irinotecan into SN-38) as compared to the human counterparts leads to 70% 
irinotecan conversion into SN-38 in mice as opposed to less than 10% in 
humans [18, 19, 29, 30]. As a consequence of this, higher tumor exposure to 
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SN-38 might be achieved in the murine model. Further evidence supports that 
increased SN-38 exposure in tumors leads to improved survival of mice with 
aggressive neuroblastoma [31]. 
The identification of the pharmacokinetic limitations of irinotecan warranted the 
development of several DDS carrying SN-38 for systemic and local 
administration [32, 33]. In our study, an electrospun nanofiber matrix made of 
an approved biodegradable biocompatible polyester, PLA, was chosen as drug 
carrier because the shape and malleability of the matrix is adaptable to the 
surgical bed that may vary between patients. The manufacturing process 
(simultaneous microcrystal spraying during polymer electrospinning) was 
selected after a series of preliminary feasibility studies where the drug was 
blended with the polymer solution and electrospun, an approach that resulted in 
extremely slow delivery rates controlled mainly by the polymer degradation 
(data not shown and [33]). The final configuration took advantage of the poor 
solubility and dissolution rate of SN-38 in the physiologic medium that was slow 
enough to produce a bimodal release kinetics, as demonstrated in vitro and in 
vivo (Figure 2A,B). This type of release is likely clinically relevant because 
initially faster release would achieve high local drug concentration (as we 
demonstrate by the microdialysis sampling approach), whereas long-lasting 
release at a slower rate could be important for recruiting more tumor cells at the 
S-phase of the cycle. Because the microcrystals are incrusted in the internal 
layers of the nanofiber matrix, the drug cannot be released from the DDS unless 
the fluids permeating through the highly porous nanofiber mesh solubilize it. 
To demonstrate that the drug crystals loaded in the polymeric matrix provide a 
sustained localized release and confer long-term antitumor activity, we 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
27 
 
performed two specifically designed in vitro experiments (preconditioning in 
culture medium and co-incubation with blank matrices). In fact, preservation of 
long term activity might be related to the chemical stabilization of the SN-38 
lactone in the hydrophobic PLA matrix, in line with previous studies reporting 
that campthothecins loaded in polymers or gels were stabilized in the active 
lactone form [34-37]. Drugs blended in polymers are usually in molecular 
dispersion (amorphous) and not crystalline [38]. Our work shows for the first 
time that microcrystals of a poorly water-soluble hydrolysable drug such as SN-
38 could be stabilized by incorporation into the nanofiber mesh. 
One fundamental contribution of our research in pediatric cancer is the 
application of the microdialysis method to study local drug delivery to the tumor 
bulk in vivo. In this work, we showed that the local penetration was restricted to 
2 mm depth into the solid tumor tissue. These findings are consistent with the 
report of Arifin et al. using computer simulation that showed penetration of less 
than 2 mm after local (intracerebral) BCNU release from Gliadel implants [14]. 
Interestingly, the Arifin study defined the term “therapeutic penetration” as “the 
length from the remnant tumor interface for which the drug concentration is 
above the therapeutic concentration” [14]. Other authors have used terminal 
sampling methods to propose that localized drug delivery might achieve such 
therapeutic penetration to ratios greater than 2 mm [38]. However, we suggest 
that the terminal sampling methods (after animal death) might have 
overestimated the drug penetration distance due to maintained drug release 
from the DDS into the tissue until sample collection. For instance, in a previous 
study, we demonstrated that upon local administration in the periocular space of 
topotecan, another camptothecin used in the treatment of pediatric solid tumors 
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like retinoblastoma, postmortem sampling dramatically increased topotecan 
levels in the posterior segment of the eye (an organ with positive pressure, like 
most solid tumors). The reason for this observation would be the termination of 
the active drug elimination process upon the animal death [39]. In another study 
of local drug release in ocular cancer, we increased intraocular drug distribution 
by the administration of concomitant local adrenaline to inhibit local blood flow 
[40]. We thus speculate that the inclusion of vasoconstrictors in the local DDS 
might help achieve deeper therapeutic drug penetration in solid tumors and 
further studies will be focused on this topic. 
Previous preclinical models of local DDS activity against extracranial tumors 
have been based on the insertion of the local DDS next to intact solid tumors 
established in mice, either in s.c. or orthotopic location. In such scenario, local 
DDS releasing paclitaxel and cisplatin have performed poorly to control s.c. 
glioma xenografts [41] and mouse uterine tumors [42], respectively. Such 
results could be explained by our studies of therapeutic penetration into the 
solid tumor bulk. In contrast, other preclinical models reproduced the context of 
“microscopic tumor rests”, either by the injection of cancer cells on top of a 
previously implanted local DDS [37] or by the total macroscopic resection of 
established xenografts previous to the insertion of the local DDS [43-45]. Such 
strategies have been used in the work of Grinstaff and Colson to study the 
activity of hydroxycampthothecin-loaded DDS polymer films against lung 
carcinoma cells [37] and paclitaxel-loaded films against non-small-cell lung 
cancer cell line xenografts [44] and sarcoma xenografts [43], achieving 
prolonged control of local tumor recurrences. 
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The results of our local pharmacokinetic studies led us to design preclinical in 
vivo models resembling subtotal tumor resection surgery. Such surgical model 
is likely the most realistic approach to study the activity of local DDSs in 
pediatric oncology because in most patients, especially the ones with stage 4 
neuroblastoma, tumors infiltrate or invade tissues surrounding vital vascular 
structures, a phenomenon that precludes complete tumor resection. 
Importantly, a recent study has reported on the activity of a doxorubicin-loaded 
local DDS to control neuroblastoma local recurrences after subtotal resection of 
orthotopic xenografts of neuroblastoma cell lines [46]. Because SN-38 is not in 
the standard of care regimen of the pediatric oncologic disease (as opposed to 
doxorubicin), our candidate DDS would provide an additional alternative in 
patients previously exposed to doxorubicin and showing resistance or tumor 
relapse. In addition, we performed all the in vivo activity studies in PDX models 
because they are likely more predictive of drug activity than cell lines and 
represent a first step towards a personalized therapy [47]. The Ewing sarcoma 
model HSJD-ES-001 is a subset of aggressive tumor with STAG2 and p53 
mutation [48], whereas the neuroblastoma HSJD-NB-005 was derived from a 
stage 4 neuroblastoma tumor with amplification of MYCN and mutation of p53. 
Our first set of in vivo studies in mice with bilateral tumors confirmed local 
activity of the DDS, because control tumors contralateral to the local DDS did 
not respond to local treatment upon subtotal bilateral resection (Figure 7). Such 
selective local activity is further supported by the finding of almost undetectable 
plasma SN-38 levels upon administration of the matrices, so that contralateral 
tumors are not exposed to SN-38 (Figures 4-6). The survival experiment on the 
neuroblastoma PDX model confirmed that the local DDS provided significant 
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control of tumor recurrence, whilst equimolar injections of irinotecan (either local 
or systemic) did not perform better than the control treatment with blank 
matrices. Because a few tumors responded in the group receiving systemic 
irinotecan upon resection, we did not find a significant difference in survival 
between the group receiving SN-38 matrices and the one receiving systemic 
irinotecan. Nevertheless, systemic treatment immediately after resection is not a 
clinically acceptable practice because it interferes with the surgical recovery. 
In summary, we have addressed an unmet medical need in pediatric oncology 
by developing an advanced DDS that localizes the release of an anticancer 
drug with broad activity spectrum in pediatric cancers. We have also 
characterized local drug distribution, a procedure that we believe is critical to 
select the patients that would likely benefit of this novel therapeutic approach. 
Moreover, due to the potency of the model drug employed for the development, 
the system could be applicable to other oncologic diseases in which local 
control is crucial for the improvement of the therapeutic index. Ongoing work in 
the laboratory is focused on the activity of the new DDS on orthotopic pediatric 
tumor PDX models, and in the study of the systemic and local toxicology of the 
DDS upon administration next to vital organs like vessels, nerves and viscera. 
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Table 1. Clinical details of the PDX models. 
Model 
code
Source of 
biopsy1
 Age at 
biopsy
Primary 
tumor 
Age at 
diagnosis
Metastasis at 
diagnosis
Demography Tumor properties Patient 
status
HSJD-
NB-005
Tumor refractory 
to treatment 
(metastasis in 
bone marrow) 
2.5 y Mass 
arising from 
kidney 
 2.0 y Yes (ganglia, 
bone marrow, 
lungs) 
Female, white Stage 4 neuroblastoma, 
MYCN amplified, P53 
mutation 
Died of 
disease
HSJD-
ES-001
Local relapse in 
scapula
2
21.7 y Scapula 17 y Yes (lungs, 
bone, bone 
marrow) 
Male, white EWS-FLI1 fusion gene, 
STAG2 mutation, P53 
mutation 
Died of 
disease
1Tumor tissue was collected with informed consent under an Institutional Review Board-approved protocol. 
2 Further details on this tumor are published in [23], named after the code SJDES023. 
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Table 2. Antiproliferative activity of SN-38 (stock solution in DMSO) against pediatric solid tumor models. 
Model Properties IC50 (nM) 95% confidence interval (nM) 
LAN-1 NB cell line 60.8 33.1-111 
SK-N-AS NB cell line 215 162-284 
HSJD-NB-005 NB PDX primary culture 25.2 17.1-37.1 
SK-ES-1 ES cell line 0.927 0.747-1.15 
HSJD-ES-001 ES PDX primary culture 1.48 1.06-2.06 
Rh30 aRMS cell line 7.57 4.62-12.4 
NB: neuroblastoma; ES: Ewing sarcoma; aRMS: alveolar rhabdomyosarcoma 
